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ARTICLE
Biallelic C1QBP Mutations Cause Severe Neonatal-,
Childhood-, or Later-Onset Cardiomyopathy Associated
with Combined Respiratory-Chain Deficiencies
Rene´ G. Feichtinger,1,19 Monika Ola´hova´,2,19 Yoshihito Kishita,3,4,19 Caterina Garone,5,13,19
Laura S. Kremer,6,7,19 Mikako Yagi,8 Takeshi Uchiumi,8 Alexis A. Jourdain,9,10 Kyle Thompson,2
Aaron R. D’Souza,5 Robert Kopajtich,6 Charlotte L. Alston,2 Johannes Koch,1 Wolfgang Sperl,1
Elisa Mastantuono,6,7 Tim M. Strom,6,7 Saskia B. Wortmann,1,6,7 Thomas Meitinger,6,7,11
Germaine Pierre,12 Patrick F. Chinnery,5 Zofia M. Chrzanowska-Lightowlers,2 Robert N. Lightowlers,2
Salvatore DiMauro,13 Sarah E. Calvo,9,10 Vamsi K. Mootha,9,10 Maurizio Moggio,14 Monica Sciacco,14
Giacomo P. Comi,15 Dario Ronchi,15 Kei Murayama,16 Akira Ohtake,17 Pedro Rebelo-Guiomar,5,18
Masakazu Kohda,3,4 Dongchon Kang,8 Johannes A. Mayr,1,20 Robert W. Taylor,2,20 Yasushi Okazaki,3,4,20
Michal Minczuk,5,20 and Holger Prokisch6,7,20,*
Complement component 1 Q subcomponent-binding protein (C1QBP; also known as p32) is amulti-compartmental protein whose pre-
cise function remains unknown. It is an evolutionary conservedmultifunctional protein localized primarily in themitochondrial matrix
and has roles in inflammation and infection processes, mitochondrial ribosome biogenesis, and regulation of apoptosis and nuclear
transcription. It has an N-terminal mitochondrial targeting peptide that is proteolytically processed after import into the mitochondrial
matrix, where it forms a homotrimeric complex organized in a doughnut-shaped structure. Although C1QBP has been reported to exert
pleiotropic effects on many cellular processes, we report here four individuals from unrelated families where biallelic mutations in
C1QBP cause a defect in mitochondrial energy metabolism. Infants presented with cardiomyopathy accompanied by multisystemic
involvement (liver, kidney, and brain), and children and adults presented with myopathy and progressive external ophthalmoplegia.
Multiple mitochondrial respiratory-chain defects, associated with the accumulation of multiple deletions of mitochondrial DNA in
the later-onset myopathic cases, were identified in all affected individuals. Steady-state C1QBP levels were decreased in all individuals’
samples, leading to combined respiratory-chain enzyme deficiency of complexes I, III, and IV. C1qbp/ mouse embryonic fibroblasts
(MEFs) resembled the human disease phenotype by showing multiple defects in oxidative phosphorylation (OXPHOS). Complementa-
tion with wild-type, but not mutagenized, C1qbp restored OXPHOS protein levels and mitochondrial enzyme activities in C1qbp/
MEFs. C1QBP deficiency represents an important mitochondrial disorder associated with a clinical spectrum ranging from infantile
lactic acidosis to childhood (cardio)myopathy and late-onset progressive external ophthalmoplegia.
Introduction
Mitochondrial disorders are an extremely heterogeneous
group of inborn errors of metabolism and encompass a
wide range of clinical presentations, such that approxi-
mately 300 disease-associated genes have been identified
to date.1,2 Mitochondrial dysfunction mainly affects or-
gans with high energy requirements, such as the brain,
central nervous system, muscle, and heart. The broad clin-
ical and genetic presentation of mitochondrial disorders
makes the molecular diagnosis challenging. Mutations
can directly affect oxidative phosphorylation (OXPHOS)
subunits or indirectly impair OXPHOS activity by
disturbing mitochondrial homeostasis. Next-generation
sequencing techniques (gene panels and exome and
genome sequencing) are proving to be an appropriate
tool for the diagnosis of this broad clinical group. However,
any diagnostic approach continues to rely upon deep
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clinical phenotyping in association with the evaluation of
OXPHOS enzymes in tissues of affected individuals.3–6
Combined defects of complexes I, III, IV, and V are typi-
cally due to deficiencies involving the homeostasis of
mitochondrial DNA (mtDNA), including defects in replica-
tion, RNA metabolism, and translation.1,7 Moreover,
mtDNA rearrangements can lead to combined OXPHOS
deficiencies; single, large-scale mtDNA deletions, predom-
inantly found in sporadic cases, are associated with Pear-
son syndrome (MIM: 557000), Kearns-Sayre syndrome
(MIM: 530000), or progressive external ophthalmoplegia
(PEO; OMIM phenotypic series PS157640), as well as late-
onset PEO due to Mendelian-driven multiple mtDNA dele-
tions, which have been observed in >20 genetically
distinct disorders8 (also see GeneReviews in Web Re-
sources). In addition, cofactor deficiencies and further
defects of mitochondrial homeostasis—including mito-
chondrial biogenesis, lipid metabolism, protein import,
fission and fusion, and quality control—can result in a
deficiency of more than one OXPHOS enzyme.2
One protein involved in mitochondrial homeostasis is
complement component 1 Q subcomponent-binding pro-
tein (C1QBP; also known as p32). It is an evolutionary
conserved and ubiquitously expressed multifunctional
protein and has been reported to be a predominantly mito-
chondrial matrix protein involved in inflammation and
infection processes, mitochondrial ribosome biogenesis,
regulation of apoptosis and nuclear transcription, and
pre-mRNA splicing.9–15 By analyzing a C1QBP-knockout
(KO) mouse model, we have previously demonstrated
that a main function of C1QBP is a combined respira-
tory-chain complex deficiency due to severely impaired
mitochondrial protein synthesis.16 Furthermore, the
Saccharomyces cerevisiae ortholog of human C1QBP,
MAM33 (mitochondrial acidic matrix protein 33), has
been shown to localize to the mitochondrial matrix.17
MAM33-deficient yeast cells show a disturbed mainte-
nance of the mitochondrial genome, impairment of mito-
chondrial ATP synthesis, and growth deficiency.17,18 The
latter can be restored by the introduction of human
C1QBP cDNA, which demonstrates the evolutionarily
conserved function of C1QBP homologs among eukary-
otes.18 In line with the complementation in yeast and find-
ings in mice, human C1QBP-knockdown (KD) cells also
exhibit reduced synthesis of mtDNA-encoded OXPHOS
polypeptides.19
Here, we report four individuals from unrelated families
affected by biallelic mutations in C1QBP (MIM: 601269).
TheypresentwithmultipleOXPHOSdeficiencies andaclin-
ical spectrum ranging from infantile lactic acidosis, child-
hood- or adulthood-onset (cardio)myopathy, and PEO.
Subjects and Methods
All studies were completed according to local ethical approval
of the institutional review boards of Technische Universita¨t
Mu¨nchen, the University of Milan, the National Research Ethics
Service Committee North East – Newcastle & North Tyneside 1,
and Saitama Medical University. In agreement with the Declara-
tion of Helsinki, all individuals or their guardians gave written
informed consent before undergoing evaluation and testing,
which was approved by the ethical committees of the centers
participating in this study, where biological samples were
obtained.
Subjects
Individual 1 (S1; family 1 individual II-2) was a boy who died at
day 18 after experiencing asymmetric ventricular cardiomyopa-
thy, congenital nephrosis, hypothyroidism, and encephalopathy
with multiple hemorrhagic events (Table 1). He was born by spon-
taneous vaginal delivery to healthy, unrelated British parents after
in vitro fertilization at 34 weeks þ 2 days of gestation. His twin
brother is unaffected. Oligohydramnios was referenced in the
antenatal history, and a swollen face, hands, and feet were noticed
at birth. On the third day, he presented with prolonged cardiore-
spiratory arrest. He was resuscitated for 2 hr by both mechanical
(chest compression) and pharmacological (adrenaline, sodium bi-
carbonate, atropine, and calcium chloride) treatments and was in-
tubated and ventilated. After resuscitation, he was admitted to
pediatric intensive care unit with severe metabolic acidosis
(plasma lactate: 21 mmol/L, normal: 0.5–2.5 mmol/L; base excess
[BE]: 18.4 mmol/L, normal: 2 to þ2 mmol/L), initial signs of
kidney failure (anuria; albumin: 15 g/L, normal: 35–40 g/L; urea:
6.1 mmol/L, normal: 0.8–5.5 mmol/L), and a poor general condi-
tion (unconscious, not responsive to stimuli, and fixed and dilated
pupils). An increased level of troponin suggested severe myocar-
dial damage secondary to his arrest event, and echocardiography
revealed a dilated and poorly functioning left ventricle. He
required additional cardiovascular and metabolic support and a
blood transfusion. Neurological investigations demonstrated
extensive brain damage: electrical discharges defined as suppres-
sion bursts and subclinical seizures were recorded by electroen-
cephalography, and brain MRI showed global cerebral edema
with a loss of differentiation between gray and white matter, a
loss of definition of the basal ganglia on T2-weighted images, mul-
tiple areas of hemorrhage in the bilateral subdural region over
both cerebral convexities and in the posterior fossa, and subarach-
noid hemorrhage in the Sylvian fissures and lateral ventricles.
Although he presented with signs and symptoms of congenital
nephrosis, his kidney ultrasound showed only general hyperecho-
genicity. During the clinical course, his neurological conditions
slightly improved: he was able to open his eyes and respond to
stimuli, and he showed some movement of the legs and arms in
the following days. However, lactic acidosis persisted, anuria was
resistant to pharmacological treatment, and he also developed hy-
perkalemia and hyperphosphatemia after blood transfusion,
which required peritoneal dialysis (day 4). The clinical course
was also complicated by thrombocytopenia on day 6 (which
required platelet transfusion), evidence of disseminated intravas-
cular coagulopathy on day 7 (which was treated with fresh frozen
plasma and cryoprecipitate), and peritonitis on day 9 (which was
treated with antibiotics). The cause of death on day 18 was respi-
ratory insufficiency. Kidney histology on autopsy tissue showed
multifocal and diffuse cortical necrosis, multifocal pyramid necro-
sis, confluent recent hemorrhages surrounding the pyramids, scat-
tered cortical tubular microcysts, and partially or completely
sclerosed glomeruli. The number of glomeruli was slightly higher
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than in normal kidney tissue and showed a different degree of me-
sangial proliferation. There were also some fibrin thrombi in the
glomerular capillaries. Necrosis and multifocal areas of hemor-
rhage were also present in the lungs, adrenals, spleen, and testes.
Histological examinations of heart autopsy tissue revealed the
presence of a small recent infarct of the anterior papillary muscle
and some hemorrhages and sparse neutrophils around a small
recent fibrous scar of the papillar muscle. The thymus showed
marked atrophy. The cortex, medulla, and crowded Hassal’s cor-
puscles were not distinguishable. A pronounced lymphocyte
depletion was present.
Individual 2 (S2; family 2 individual II-1) was a girl who died at
4 days of age after suffering from cardiomegaly and lactic acidosis.
She was the first child of healthy, non-consanguineous Japanese
parents. Pregnancy was complicated by intrauterine growth re-
striction and oligohydramnios. She was born pre-term (33 weeks
of gestation) by emergency cesarean section as a result of fetal
heart-rate failure. In the immediate postnatal period, she devel-
oped metabolic acidosis (BE: 25 mmol/L, normal: 2 to
þ2 mmol/L) and an increased level of lactic acid (9.0 mmol/L at
day 0, 19.8 mmol/L at day 1, >20 mmol/L at day 3, and
19.6 mmol/L at day 4; normal: 0.5–2.5 mmol/L). She became
Table 1. Genetic and Clinical Findings in Individuals with C1QBP Mutations
Proband
S1 S2 S3 S4
C1QBP variant
(GenBank:
NM_001212.3)
c.[557G>C];[612C>G] c.[739G>T];[c.824T>C] c.[823C>T];[823C>T] c.[562_564delTAT];[562_
564delTAT]
C1QBP variant
(GenBank:
NP_001203.1)
p.[Cys186Ser];[Phe204Leu] p.[Gly247Trp];[Leu275Pro] p.[Leu275Phe];[Leu275Phe] p.[Tyr188del];[Tyr188del]
Origin European descent Asian descent European descent European descent
Age of onset 4 days birth 5 years 57 years
Gender male female male male
Current age or age
of death
18 days (deceased) 4 days (deceased) 22 years (alive) 70 years (deceased)
Antenatal findings oligohydramnios, oedematus
feet, face and hands
IUGR, oligohydramnios – –
Plasma metabolic
test results
lactate: 21 mmol/L (normal:
0.5–2.5)
lactate: 20 mmol/L
(normal: 0.5–2.5)
lactate: 3.2 mmol/L (normal:
0.5–2.5); CPK: 566 U/L
(normal: 38–174); Met:
56.2 mmol/L (normal: 14.4–36);
Tyr: 145 mmol/L (normal:
41.8–108)
normal
Clinical Signs and Symptoms
Heart cardiorespiratory arrest,
asymmetric left ventricular
cardiomegaly
cardiomegaly left ventricular hypertrophy left ventricular hypertrophy
Liver – hepatomegaly increased transaminases –
CNS multiple cortical, ventricular,
and subdural hemorrhages
and cerebral edema, burst
suppression-like electrical
discharges, suclinical seizures
– NA NA
PNS NA NA sensory peripheral neuropathy diffuse neurogenic
abnormalities and focal
myogenic in the gluteus
maximus
Kidney congenital nephrosis – – NA
Muscle NA NA exercise intolerance with fatigue
and vomiting
exercise intolerance, weakness
Eye NA NA astigmatism, amblyopia,
ptosis, PEO
ptosis, progressive external
opthalmoplegia
Other hypothyroidism, disseminated
intravascular coagulopathy
NA NA post-traumatic depression,
diabetes, sensorineural
hearing loss
Abbreviations are as follows: NA, not available; CPK, creatine phosphokinase; Met, methionine; Tyr, tyrosine; IUGR, intrauterine growth restriction; CNS, central
nervous system; and PNS, peripheral nervous system.
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unconscious and required ventilator support. Cardiomegaly with
no ventricular or septic hypertrophy was diagnosed by heart ultra-
sound and a thoracic X-ray scan. A general examination revealed
that she also presented with mild hepatomegaly, and histological
examination of a liver biopsy showed marked lipid accumulation.
Additional neurological signs and symptoms were not reported,
and brain ultrasound did not reveal any abnormalities. She died
on the fourth day of life because of cardiorespiratory insufficiency.
Individual 3 (S3; family 3 individual II-2) is a 22-year old man
with myopathy, asymmetric ventricular cardiomyopathy, PEO,
and ptosis. He was born after an uneventful pregnancy to non-
consanguineous Austrian parents. His sister, who is 3 years older,
is healthy. Pregnancy and peri- and postnatal adaptations were un-
remarkable. Birth weight, length, and head circumference were
within normal limits. His early milestone acquisitions were appro-
priate for his age. He presented with bilateral hyperopic astigma-
tism and amblyopia, a first sign of eye muscular weakness, at
5 years of age and exercise intolerance with fatigue, episodes of
vomiting, and elevated levels of creatine phosphokinase (CPK)
1 year later. Left ventricular cardiomyopathy was also diagnosed
at 8 years of age after heart ultrasound screening. The clinical
phenotype and increased level of plasma lactate (3.2 mmol/L,
normal: 0.5–2.2 mmol/L) were suggestive of a mitochondrial dis-
order. Treatment with L-carnitine, riboflavin, and coenzyme Q
was initiated but showed only initial and partial improvement.
The clinical course appeared slowly progressive with the develop-
ment of mild ptosis at 14 years of age and PEO at 19 years of age.
Transaminase levels were repeatedly elevated (aspartate transami-
nase: 73 U/L, normal: 10–50 U/L; alanine transaminase: 61 U/L,
normal: 10–50 U/L), and liver ultrasound showed no structural
changes. At the last evaluation, a nerve conduction study revealed
subclinical signs of sensory peripheral neuropathy, and scotopic
and photopic bilateral electroretinography showed low ampli-
tudes. Assessment of exercise intolerance by bicycle ergometry
confirmed premature fatigue and an increased level of plasma
lactate (basic lactate: 6.1 and 19.1 mmol/L after exercise, normal:
0.5–2.2 mmol/L) and CPK (basic CPK: 386 and 566 U/L after exer-
cise, normal: 38–174 U/L). The cardiac status was stable without
progression. He was investigated for hearing and kidney function-
ality, which were shown to be normal. Although he has general-
ized weakness, he is not compromised in his daily functionality.
Individual 4 (S4; family 4 individual II-2) was a 61-year-old man
with late-onset PEO andmyopathy. Hewas born at term as the sec-
ond of ten brothers and sisters to healthy, non-consanguineous
Italian parents after an uneventful delivery. No family history of
neuromuscular disorders or other disorders, except for the prema-
ture postnatal death of one sister, has been reported. Early devel-
opment and milestone acquisition were referenced as normal. At
the age of 57 years, he was admitted to a psychiatric hospital
because of post-traumatic depression that required intensive phar-
macological and psychotherapy intervention. He was also diag-
nosed with diabetes and started treatment with gliclazide. The
onset of neuromuscular weakness was detected at 59 years of
age, and rapidly progressive exercise intolerance limited his func-
tionality: he was not able to stand for long periods of time or raise
his arms. He was admitted to the hospital at 61 years of age
because of the development of ptosis, severe constipation, and
weight loss (10 kg in 5 months). At the neurological examination,
he presented with important bilateral eyelid ptosis (left > right),
PEO in all directions, mild to moderate proximal weakness, mild
and diffuse hypotrophy, and an unstable gait due to lower-
limb weakness. Electromyography showed diffuse signs of chronic
neurogenic rearrangement and focalmyogenic signs in the gluteus
maximus. A metabolic workup including plasma lactate, creatine
kinase, transaminases, and thyroid function was normal. He was
extensively investigated, and additional clinical findings were
identified: left ventricular hypertrophy, left ventricular overload,
and signs of previous myocardial infarction by electrocardiog-
raphy; bilateral and symmetric sensorineural hypoacusia by audi-
ometry; and multiple gastric erithematous areas by esophagogas-
troduodenoscopy. Proband S4 and his family refused additional
investigations. He died in his 70s for an unknown reason.
Exome Sequencing
We applied next-generation exome sequencing with whole-
exome sequencing (WES) or a mitochondrial exome library
(‘‘MitoExome’’) to the individuals’ DNA extracted from peripheral
blood. Probands S1–S3 were investigated by WES.4,5,20 In brief,
coding regions were enriched with a SureSelect Human All Exon
V5 Kit (Agilent) or TruSeq (Illumina) and then sequenced as
100-bp paired-end runs on an Illumina HiSeq 2000, 2500, or
4000. Reads were aligned to the human reference genome
(UCSC Genome Browser build hg19) with the Burrows-Wheeler
Aligner (v.0.7.5 a).21 Single-nucleotide variants and small inser-
tions and deletions (indels) were detected by SAMtools
(v.0.1.19). Proband S4 was investigated by MitoExome as previ-
ously described,22 and only rare recessive variants in highly
conserved amino acid residues were considered pathogenic by
PolyPhen-2 or SIFT (Table S1).
We used Sanger sequencing to confirm the identified mutations
and test the carrier status of unaffected family members.
mDNA Analysis
mtDNA was amplified with two primer pairs, giving a 16,147 bp
(F1) or 15,679 bp (F2) fragment. 5 mL of the amplified mtDNA
was loaded onto a 0.7% agarose gel and separated at 80 V for
1 hr. The marker l/HindIII (the bacteriophage l digested by
HindIII) was used.23 Southern blot was performed as previously
described.24 mtDNA copy number was determined by quantitative
real-time PCR with four different nuclear and two mitochondrial
PCR amplicons.25 The relative amount of mtDNA versus nuclear
DNA was calculated by the 2DDCT method.25
OXPHOS Enzyme Activities
Muscle tissues (20–100 mg) were homogenized in extraction
buffer (20 mM Tris-HCl [pH 7.6], 250 mM sucrose, 40 mM KCl,
and 2mM EGTA). The post-nuclear supernatant isolated by centri-
fugation at 6003 g and containing themitochondrial fraction was
used for measurement of enzyme activities. OXPHOS enzyme and
citrate synthase (CS) activity was measured spectrophotometri-
cally as previously described.26–29
Western Blot Analysis
Skeletal muscle and fibroblast homogenates were obtained accord-
ing to previously described methodologies.30 30–40 mg (S1–S3)
and 20 mg (S4) of whole-cell protein extracts were separated by
SDSpolyacrylamide (12%) electrophoresis and thenwet transferred
to polyvinyl difluoride (PVDF) membranes. For S4, a 4%–12%
gradient gelwasused. Immunological detectionof proteinswas car-
ried out with the following primary antibodies: C1QBP (ab24733,
Abcam), b-actin (A1978, Sigma), a-tubulin (ab7291, Abcam), and
OXPHOS complex-specific antibodies (NDUFS3 [ab14711, Abcam],
NDUFB8 [ab110242, Abcam], NDUFA9 [MS111,Molecular Probes],
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SDHA [459200, MitoSciences], SDHB [ab14714, Abcam], UQCRC2
[ab14745, Abcam], COXI [ab14705, Abcam], COXII [ab110258,
Abcam], COXIV [ab14744, Abcam], andATP5A [ab14748, Abcam]).
Species-appropriate horseradish-peroxidase-conjugated secondary
antibodies (DAKO, P0399, and P0260) were used.
BN-PAGE Analysis
For blue-native polyacrylamide-gel electrophoresis (BN-PAGE),
n-dodecyl b-D-maltoside-solubilized mitochondrial membranes
were prepared from isolated fibroblasts and muscle mitochondria
according to previously described methodologies.30,31 In brief,
100 mg of mitochondrial extracts was loaded onto a 4%–16%
native polyacrylamide BisTris gradient gel (Life Technologies)
and separated electrophoretically. For western blot analysis,
samples separated by BN-PAGE were transferred onto PVDF
membranes and subjected to the following primary antibodies:
NDUFB8 (complex I [CI]), SDHA (complex II [CII]), UQCRC2
(complex III [CIII]), COXI (complex IV [CIV]), and ATP5A (com-
plex V [CV]).
Immunofluorescence Staining
Immunofluorescence was performed according to a modified
version of the previously published protocol.32 Fibroblasts were
grown on coverslips, washed with PBS, and fixed with 4% formal-
dehyde for 15 min at room temperature. After additional washes
with PBS, coverslips were permeabilized with 1% Triton X-100
for 5 min, washed, and blocked in 5% fetal bovine serum (FBS)
for 1 hr at room temperature. A solution of primary antibodies
(1:500 polyclonal rabbit anti-TOM20, sc-11415, Santa Cruz;
1:250 monoclonal mouse anti-C1QBP, ab24733, Abcam) in 5%
FBS was prepared and used for incubating the coverslips for 1 hr
at room temperature. After PBS washings, coverslips were incu-
bated with secondary antibodies (1:1,000 Alexa-Fluor-488-conju-
gated goat anti-mouse IgG, A11001, Invitrogen; 1:1,000 Alexa-
Fluor-594-conjugated goat anti-rabbit IgG, A11012, Invitrogen)
in 5% FBS for 1 hr at room temperature while being protected
from light. After the final washes, coverslips were mounted
(ProLong Gold antifade reagent with DAPI, P36941, Invitrogen)
on glass slides. Microscopy was carried out with a Zeiss LSM 880
confocal microscope, and acquired images were processed with
ImageJ.33
High-Resolution Respirometry
Mouse embryonic fibroblasts (MEFs) were seeded at a density of
20,000 cells/well in 80 mL of culture media in an XFe 24-well
cell-culture microplate (Seahorse Bioscience) and incubated over-
night at 37C in 5% CO2. Culture medium was replaced with
180 mL of bicarbonate-free DMEM, and cells were incubated at
37C for 30 min before measurement. The oxygen-consumption
rate (OCR) was measured with an XFe 24 Extracellular Flux
Analyzer (Seahorse Biosciences) and determined (1) with no
additions (basal respiration), (2) after the addition of 0.5 mM oli-
gomycin (indicating ATP production), (3) after the addition of
1 mM carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
(maximal respiration), and (4) after the addition of 1 mM rote-
none and antimycin A (non-mitochondrial respiration) (addi-
tives were purchased from Sigma at the highest quality). The
difference in OCR after the addition of oligomycin and the
non-mitochondrial respiration specify proton leakage, and
the difference between basal and maximal respiration determines
spare capacity.
Construction and Validation of C1QBP Expression
Vector
The mouse C1QBP variants p.Glu244Trp and p.Leu272Pro (corre-
sponding to the human variants p.Gly247Trp [c.739G>T] and
p.Leu275Pro [c.824T>C], respectively, found in probands S2 and
S3) were generated from pcDNA3-p32-IRES-GFP by PCR-based
site-directed mutagenesis and confirmed by sequencing. To
examine protein expression, we transfected C1qbp-KO MEFs
with theC1qbp expression vector by using the transfection reagent
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. GFP expression served as an internal control.
mRNA Quantification
Total RNA from wild-type (WT) MEFs and C1qbp-KO MEFs trans-
fected with various C1qbp expression vectors was isolated with
an RNeasy Mini Kit (QIAGEN) according to the manufacturer’s in-
structions. The concentration and purity of total RNA were
measured on a NanoDrop spectrophotometer (NanoDrop Tech-
nologies). Reverse transcription of 1 mg of total RNAwas performed
with a PrimeScript RT Reagent Kit (TAKARA). Mouse C1qbpmRNA
and mouse 18S ribosomal RNA (control) were detected by quanti-
tative PCR with SYBR Premix Ex Taq II (TAKARA) and a thermal
cycler (StepOnePlus, Applied Biosystems). Primers were as follows:
50-CGCGGTTCTATTTTGTTGGT-30 (18S rRNA forward), 50-AGTCG
GCATCGTTTATGGTC-30 (18S rRNA reverse), 50-GGCCTTCGTTG
AATTCTTGA-30 (C1qbp mRNA forward), and 50- GCCTCATCT
TCGTGTCCAAT-30 (C1qbp mRNA reverse). An unpaired Student’s
t test was used to determine statistical differences between two
groups. Values of *p < 0.05, **p < 0.01, and ***p < 0.005 were
considered to be statistically significant.
Results
Exome Sequencing and Variant Prioritization
Clinical research centers fromAustria, Germany, Japan, the
UK, and the US independently achieved and subsequently
shared results from WES or MitoExome sequencing anal-
ysis on individuals with suspected mitochondrial disease.
WES of probands S1–S3 failed to identify likely or known
disease-associated genetic variants but did reveal rare bial-
lelic variants (minor allele frequency [MAF] < 0.1% in
public and in-house databases) in C1QBP (GenBank:
NM_001212.3). Screening of our in-house database of
more than 10,000 WES datasets of individuals with non-
mitochondrial disease revealed no additional individual
with biallelic rare variants in C1QBP. Filtering for genes
coding for mitochondrial proteins in probands S1–S3 re-
vealed that C1QBP was the only gene with biallelic
variants.34 Likewise, MitoExome sequencing prioritized
biallelic variants in C1QBP in proband S4. Altogether, we
identified four individuals harboring recessive variants in
C1QBP (Table 1 and Figure 1A). Although none of the iden-
tified variants are predicted to cause a loss of function, all
are predicted to be pathogenic (Figure 1B and Table S1).
Human C1QBP (UniProt: Q07021) forms a homotrimer
arranged into a doughnut-shaped structure with an unusu-
ally asymmetric charge distribution on the surface. The
variants p.Cys186Ser, p.Gly247Trp, and p.Leu275Pro are
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all localized in important structural domains of the pro-
tein. Specifically, amino acid residue Cys186 is localized
on the b5 strand of the protein, Gly247 is located on
the hydrogen-bonded turn of the protein, and Pro275
is located on the aC helix (Figure 1C). In contrast,
p.Phe204Leu and p.Tyr188del are localized on the coiled-
coil region between the b5 and b6 strands.9 All C1QBP var-
iants have been confirmed by Sanger sequencing. Homo-
zygosity or compound heterozygosity was confirmed by
segregation analysis in families 1 and 3 and by cloning
and sequencing of genomic DNA in proband S2, whereas
no DNA was available from the parents of proband S4 for
A
B
C
Figure 1. C1QBP Variants and Gene and Protein Structure
(A) Pedigrees of the investigated families (S1–S4) affected by recessively inherited C1QBP variants. Affected individuals are indicated by
closed symbols. Both variants in proband S2 have been confirmed to be compound heterozygous by phasing of WES data.
(B) Gene structure with exons and introns shows the localization of the investigated gene variations. Conservation of the affected amino
acid residues is presented in the alignment of homologs across different species. Exons are highlighted in blue. The size of the introns was
reduced 10-fold. MTS is the mitochondrial target sequence. MAM33 (mitochondrial acidic matrix protein 33) is the Saccharomyces
cerevisiae homolog of C1QBP.
(C) Inspection of the protein structure was performed with PyMOL (PDB: 1P32). A monomer is presented on the left, and the trimer is in
the center. The electrostatic field of the trimer is indicated to the right (negative polarity, red; positive polarity, blue). Affected residues are
colored in one of the monomers: Cys186, green; Tyr188, blue; Phe204, red; Gly247, magenta; and Leu275, orange.
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validation of the deletion’s homozygosity. The C1QBP
variants found in proband S2 have previously been
suggested as likely candidates but have not been validated
so far.4
Mitochondrial Respiratory-Chain Activities
The identification of rare, biallelic C1QBP variants in four
individuals with clinically and biochemically confirmed
mitochondrial disease adds further evidence for their
functional relevance. Typical of mitochondrial disorders,
the C1QBP defect resulted in a spectrum of manifestations
that ranged from infantile lactic acidosis (probands S1 and
S2) to childhood myopathy (proband S3) to late-onset
myopathy with PEO (proband S4). However, in all indi-
viduals, cardiac symptoms were present, and respiratory-
chain activities in muscle or liver homogenates showed
a severe combined deficiency of respiratory-chain activ-
ities (complexes I, III, and IV). This was accompanied
by an increased level of mitochondrial mass index
(CS) in the muscle of probands S3 (511 mUnits/mg
protein; normal: 150–325 mUnits/mg protein) and S4
(151 mUnits/mg protein; normal: 137 5 15 mUnits/mg
protein; see Table S2).
Enzymatic activities of liver homogenates from proband
S2 revealed a more general downregulation of the
OXPHOS complexes. In addition to the complex I
(to 5%), III (to 14%), and IV (to 11%) deficiency, a reduc-
tion in complex II (to 37%) activity was also found (Table
S2). In addition, decreased COX histochemical activity
was found in proband S1 (affecting up to 75% of all muscle
fibers); occasional COX-deficient fibers were observed in
muscle from probands S3 and S4, notably at levels above
those expected to be detected in age-matched control indi-
viduals as a result of somatic mtDNAmutation. Ragged-red
fibers were present in the muscle of probands S1 and S3
(Table S2). Histopathological analysis of the muscle of pro-
A B Figure 2. Western Blot Analysis of C1QBP
Cell lysates isolated from (A) the skeletal
muscle of affected probands S1, S3, and
S4 and (B) fibroblasts from probands
S1–S3 and age-matched control individuals
(C1 and C2) were analyzed. Fibroblasts
from proband S4 and skeletal muscle from
proband S2 were not available. b-actin
and a-tubulin were used as loading con-
trols. All experiments were repeated at least
two times, and representative images are
shown. Number of repeats: (A) n ¼ 3 (S1)
and n ¼ 2 (S3 and S4); (B) n ¼ 2 (S1–S3).
band S4 showed moderate variability
in fiber size, a moderate increase in fi-
ber splitting and central nuclei, and a
slight increase in connective tissue.
The identification of four different
alleles in four affected individuals
with a similar clinical and biochemical
phenotype from four families estab-
lishes C1QBP variants as confidently implicated in reces-
sively inherited mitochondrial disease.
C1QBP and OXPHOS Protein Levels
Given that previous studies have reported C1QBP as a
mitochondrial-matrix protein, we wanted to validate
the localization of C1QBP in mitochondria. Immuno-
cytochemical staining using C1QBP-specific antibodies
confirmed the mitochondrial localization of the protein
(Figure S1).9,13,17 Given that all identified C1QBP variants
affect only one amino acid, the consequences on protein
stability were unclear. We therefore investigated available
skeletal-muscle biopsy material and primary fibroblast
cultures established from individuals to analyze the
significance of C1QBP variants in disease. Western blot
analysis showed that C1QBP levels were not detectable in
muscle (Figure 2A) and considerably decreased in fibro-
blasts (Figure 2B), supporting the notion that correspond-
ing C1QBP variants adversely affect the stability of the
protein.
Consistent with the findings of enzymatic investigations
from muscle, a decrease in complex I and complex IV sub-
units was present in muscle homogenates derived from
probands S1, S3, and S4 (Figure 3A). In addition, UQCRC2
was decreased in the muscle of probands S3 and S4
(Figure 3A). In contrast, OXPHOS protein levels were
normal or only marginally lowered in fibroblasts from pro-
bands S1 and S3, whereas proband S2 showed a marked
loss of complex IV subunits (Figure 3B). Surprisingly, the
steady-state levels of complex III subunits were higher
in the fibroblasts of proband S3 than in control cells
(Figure 3B).
Decreased protein levels of subunits of respiratory-chain
complexes usually reflect assembly defects, but they can
also be suggestive of other mitochondrial disorders,
including mitochondrial translation defects. We therefore
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analyzed the steady-state levels of intact respiratory-chain
complexes by BN-PAGE. A decrease in intact steady-state
levels of complexes I, IV, and V was present in the muscle
of probands S1 and S3 (Figure 4A). Only a slight decrease in
complex IV was obvious in proband S1. The level of com-
plex II was normal. In agreement with the decrease in the
steady-state levels of complex I and complex IV subunits in
the fibroblasts of individual S2, decreased levels of assem-
bled complex I and complex IV were found (Figure 4B).
The level of complex III was normal in proband S2
(Figure 4B). No alterations in the steady-state levels of
intact complexes were detectable in fibroblasts from pro-
bands S1 and S3 (Figure 4B).
Complementation Studies with Mouse Fibroblasts
We recently showed that a KO of the orthologous C1qbp in
MEFs caused impaired mitochondrial respiration associ-
ated with reduced levels of respiratory-chain complexes I,
III, and IV.16 C1qbp/ MEFs recapitulate the human dis-
ease phenotype by displaying multiple OXPHOS defects.
We therefore took advantage of the strong phenotype in
the mouse system to investigate the functional properties
of the C1QBP variants identified in probands S2 and S3.
We modeled the variants in the mouse cDNA and ex-
pressed them in C1qbp/MEFs. With mitochondrial com-
plex IV subunits I (COXI) and III (COXIII) as markers, only
re-expression of mouse WT C1qbp rescued the amount of
A
B
Figure 3. Steady-State Levels of OXPHOS Complex Subunits
(A) Western blot analysis of OXPHOS subunits in skeletal-muscle lysates from control individuals (C1 and C2) and probands S1,
S3, and S4.
(B) Western blot analysis of OXPHOS subunits in skin fibroblasts from probands S1–S3 and age-matched control individuals (C1–C3).
OXPHOS-subunit-specific antibodies were used against NDUFB8 or NDUFA9 (CI); SDHA or SDHB (CII); UQCRC2 (CIII); COXI, COXII, or
COXIV (CIV); and ATP5A (CV). Cytosolic b-actin andmitochondrial markers porin (VDAC) and SDHAwere used as loading controls. All
experiments were repeated at least twice, and representative western blots are shown. Number of repeats: (A) n¼ 3 (S1) and n¼ 2 (S3 and
S4); (B) n ¼ 4 (S1) and n ¼ 2 (S2 and S3).
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complex IV protein (Figure 5A, upper panel, lane 3), con-
firming causality between loss of C1QBP and diminished
levels of OXPHOS subunits. Expression of C1qbp cDNA
coding the p.Gly247Trp variant (p.Gly244Trp in mice) re-
sulted in levels comparable to those of the native form
but only partially rescued COX subunit levels (Figure 5A,
upper panel, lane 4), confirming a functional defect.
Expression of C1qbp cDNA encoding the p.Leu275Pro
variant (p.Leu272Pro in mice) did not result in a detectable
C1QBP and was consequently not able to rescue mito-
chondrial COXI or COXIII levels (Figure 5A, upper panel,
lane 5). GFP expression under the internal ribosome entry
site and the C1qbp mRNA level were comparable to those
of the WT (Figures 5A and 5B), suggesting that the low
expression of p.Leu272Pro is due to reduced protein
expression or increased protein turnover.
To validate the consequences on respiration, we per-
formed high-resolution respirometry with C1qbp-deficient
MEFs expressing cDNAs encoding the WT, p.Gly244Trp,
p.Leu272Pro, or an empty vector. Reduced basal and
maximal respiration, proton leakage, and ATP production
were found in cells non-transduced or transduced with
the empty vector (Figures 5C and 5D). Consistent with the
results of the western blot analysis, p.Gly244Trp resulted
in a partial recovery, whereas p.Leu272Pro was in a range
similar to that of the empty vector (Figures 5C and 5D).
In summary, complementation with WT, but not
mutant, C1qbp in C1qbp/ MEFs restored C1QBP steady-
A
B
Figure 4. BN-PAGE of OXPHOS Com-
plexes
One-dimensional BN-PAGE analysis of
OXPHOS complexes was performed on
mitochondrial lysates isolated from pro-
bands’ (A) skeletal muscle (S1 and S3)
and (B) fibroblasts (S1–S3) and age-
matched control individuals (C1 and C2).
The assembly of OXPHOS complexes was
assessed by western blotting with anti-
bodies against NDUFB8 (CI), SDHA (CII),
UQCRC2 (CIII), COXI (CIV), and ATP5A
(CV). An antibody against complex II sub-
unit SDHA was used as a loading control.
The ATP5A antibody detected two bands:
the fully assembled complex V (F0F1) and
the soluble F1 subunit. The asterisk indi-
cates a longer exposure time for the CV
F1 subunit. All experiments were repeated
at least twice, and representative images
are shown. Number of repeats: (A) n ¼ 4
(S1) and n ¼ 2 (S3); (B) n ¼ 4 (S1) and
n ¼ 2 (S2 and S3).
state level, OXPHOS protein expres-
sion, and enzyme activities.
mtDNA analysis
Given that proband S3 presented
with PEO, which is often associated
with mtDNA rearrangements, ana-
lyses of mtDNA copy number and
multiple mtDNA deletions were performed in all available
muscle and fibroblast cell lines (Table S2). These revealed
that mtDNA copy number was 250% higher in the
muscle of proband S1 and 600% higher in the liver of
proband S2 than in control cells, but there was no evi-
dence of mtDNA rearrangements (Table S2). Although
the level of mtDNAwas within the normal range inmuscle
samples from probands S3 and S4, long-range PCR and
Southern blotting both revealed evidence of multiple
mtDNA deletions (Figure 6). Concordant with other
investigations of fibroblasts from proband S3, no signifi-
cant finding (borderline) was obtained in this individual’s
cell line.
Discussion
Here, we report four individuals from unrelated families
where biallelic mutations in C1QBP cause a combined res-
piratory-chain enzyme deficiency. All variants are rare with
a MAF < 0.00005 in the ExAC Browser, and no other indi-
vidual in our in-house database of >10,000 WES datasets
carries rare biallelic variants in this gene. The finding of
four individuals with a defect in mitochondrial energy
metabolism (among 2,000 individuals investigated) pre-
sents a genome-wide-significant enrichment of biallelic
C1QBP variants (p < 0.001, Fisher’s exact test) in compari-
son with samples from non-mitochondrial disorders. In
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addition, all variants are predicted to be deleterious by
several prediction programs.
To validate the impact of the rare C1QBP variants at the
functional level, we took advantage of three established re-
sources: biopsy tissues, primary fibroblast cell lines from
three affected individuals, and C1qbp/ MEFs. Mitochon-
drial localization of C1QBP was shown by immunohisto-
chemical staining in fibroblasts. Immunodecoration using
C1QBP-specific antibodies in muscle-biopsy material ob-
tained from all individuals failed to detect C1QBP, indi-
cating a loss of function. However, when investigating
the probands’ fibroblasts, we detected low but substantial
amounts of C1QBP in all cell lines, most likely reflecting
different expression and turnover rates between muscle
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Figure 5. Complementation Studies Using C1qbp/ Mouse Fibroblasts
(A) Quantification of C1QBP, COXI, and COXIII levels. Top: WTor C1qbp KOMEFs were transfected with the pcDNA3-C1qbp-IRES-GFP
plasmid for 48 hr. Western blotting on total cell extracts was performed with anti-C1QBP, anti-COXI, anti-COXIII, anti-GFP, and anti-
VDAC antibodies. VDAC was used as the loading control. Bottom: the mean ratios of band densities in transfected MEFs from blots are
shown. Cells transfected with expression constructs for p.Gly244Trp and p.Leu272Pro variants show significantly lower amounts of
mature C1QBP and mitochondrial-DNA-encoded proteins (COXI and COXIII). The results represent the mean5 SD of three indepen-
dent experiments. ***p < 0.005 versus WT transfectant.
(B) Relative mRNA expression of C1qbp alleles normalized to mouse 18S rRNA by quantitative real-time PCR. The results represent the
mean5 SD of three independent experiments.
(C and D) Oxygen consumption rate (OCR) profile (C) and histogram of C1qbp KO cells transfected withWTandmutant C1qbp plasmid
(D). The histogram shows the basal respiration rate (basal), ATP production rate (ATP), and maximal respiration rate (maximal) calcu-
lated from OCR profiles. Data show the mean5 SD of triplicated assays. **p < 0.01 and ***p < 0.005 versus WT transfectant.
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and fibroblasts. These data argue against a loss of function
and for an adverse effect on protein stability of the identi-
fied C1QBP variants; this could lead to depletion of C1QBP
in some tissues with higher turnover rates. In any case, the
data provide additional evidence for the functional rele-
vance of the C1QBP variants.
All individuals showed a severe combined deficiency of
respiratory-chain complexes (I, III, and IV) in muscle or
liver homogenates. These findings are in line with observa-
tions in yeast and mice models, where the deficiency of
the C1QBP orthologs resulted in impairment of mito-
chondrial ATP synthesis or a combined deficiency of respi-
ratory-chain complexes, respectively.16–18 For both the
p.Gly247Trp and p.Leu275Pro variants, this deficiency
could be rescued by expression of human WT C1QBP. We
therefore leveraged the respiratory-chain deficiency in
C1qbp/ MEFs and employed it to screen for functional
complementation by the human mutations. We tested
two alleles, and whereas one allele only partially rescued
the phenotype of the fibroblasts, the other did not func-
tion at all (Figure 5). With these experiments, we provide
convincing evidence that the identified C1QBP mutations
cause a combined respiratory-chain deficiency. Analogous
to findings in mice, biallelic loss-of-function C1QBP vari-
ants might be embryonically lethal in humans.
Mutations in half of the known mitochondriopathy-
associated genes result in a combined deficiency of respira-
tory-chain enzymes.2 Combined defects are typically due
to deficiencies in mtDNA replication, transcription, or
translation. Experiments on KO mouse and KD human
cells argued for a role of C1QBP in mitochondrial protein
synthesis.16,19 Investigations on biopsy tissue from indi-
viduals with C1QBP variants confirmed this observation.
We found lower levels of various subunits of the respira-
tory chain in these samples than in age-matched control
samples (Figures 3 and 4), whereas RNA expression studies
on one cell line did not reveal any alterations in the level of
mitochondrial transcripts (data not shown). As expected
from earlier complementation studies, a role of C1QBP in
protein synthesis seems to be a conserved function of
C1QBP in mitochondria.
Interestingly, the yeast KO cells additionally showed a
disturbed maintenance of the mitochondrial genome, a
feature that has not been observed in higher eukaryotes
so far but is also not very specific in yeast given that it is
frequently found to be a result of impaired OXPHOS in
these cells.18 Multiple mtDNA deletions could also explain
a combined respiratory-chain deficiency with normal com-
plex II activity. However, multiple deletions were only
detectable in the muscle of two probands (S3 and S4),
bothofwhomhada later onset in either childhoodor adult-
hood. Becausewe foundno evidence of variablemtDNAde-
letions or mtDNA depletion in the early-onset probands S1
and S2, we can be confident that their respiratory-chain
deficiency was not caused by a disturbed maintenance of
the mitochondrial genome. Nevertheless, in humans there
is no evidence that multiple mtDNA deletions appear as a
result of impaired OXPHOS, indicating an additional func-
tion of C1QBP in the maintenance of the human mito-
chondrial genome. Given that all cells investigated so far
are acute KD or embryonic fibroblasts and, in the case of
S1 and S2, are based on biopsies taken in the first week of
life, the accumulation of detectable mtDNA deletions in
C1QBP deficiency is likely to occur over considerable
time. Wang et al. have reported on an interaction between
C1QBP and RECQ4, a helicase suggested to participate in
mtDNA maintenance.35 They describe a RECQ4 mutant
that failed to interact with C1QBP, which led to increases
in mtDNA copy number and mitochondrial dysfunction.
Such scenarios indicate multiple functions of C1QBP in
mitochondria. Indeed, a number of mitochondrial interac-
tion partners of C1QBP have been identified by proteomic
studies.36 They include a number of genes involved in iron-
sulfur biogenesis (BOLA3 [MIM: 614299], LYRM1 [MIM:
614709], LYRM2, LYRM4 [MIM: 613311], and LYRM5) or
OXPHOS subunits (ATP5A1 [MIM: 164360], C17ORF89,
COX6B1 [MIM: 124089], NDUFA4 [MIM: 603833],
NDUFAF4 [MIM: 611776], and NDUFS3 [MIM: 603846]),
as well as factors involved in the maintenance of the
mitochondrial morphology (C2ORF47 [MIM: 617267],
CHCHD2 [MIM: 616244], and CHCHD10 [MIM: 615903])
and the mitochondrial genome (TFAM [MIM: 600438]).
The multiple interaction partners of C1QBP point to a
multifunctional chaperone role of the protein.37
C1QBP defects manifested with a spectrum of symptoms
ranging from infantile lactic acidosis (in probands S1 and
A B Figure 6. Long-Range PCR and Southern
Blot of Individuals with Multiple mtDNA
Deletions and Control Individuals
(A) Long-range PCR of S3.
(B) Southern blot of proband S4. mtDNA
was amplified with two primer pairs, giv-
ing 16,147 bp (F1) and 15,679 (F2) bp frag-
ments. 5 mL of the amplified mtDNA was
loaded onto a 0.7% agarose gel and sepa-
rated at 80 V for 1 hr. Abbreviations are
as follows: S3M, muscle of proband S3;
S3F, fibroblasts of proband S3; S4, muscle
of proband S4; M, marker l/HindIII;
C1–C3: control cells.
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S2) to childhoodmyopathy, PEO, and later peripheral neu-
ropathy (in proband S3) to adult-onset myopathy with
PEO (in proband S4). All individuals presented with major
cardiac symptoms, which resulted in early death in the
neonatal form and were rather stable in individuals with
later presentation. A very recently established cardiomyo-
cyte-specific deletion of C1qbp resulted in contractile
dysfunction, cardiac dilatation, and cardiac fibrosis and
thereby confirmed an important function of C1QBP in
the heart.38 Decreased COXI and COXIII expression
confirmed the mitochondrial dysfunction that resulted
in cardiomyopathy at the age of 2 months and a median
lifespan of approximately 14 months.38
In addition, the two individuals with a late disease onset
presented with PEO and variable mtDNA deletions. The
clinical manifestation of disorders with deletions in the
mitochondrial genome is heterogeneous but often in-
cludes PEO.2 In the group of disorders with multiple
mtDNA deletions, cardiomyopathy is a rare symptom. It
is rarely reported in individuals with variants in POLG
(MIM: 258450)39–41 and TWNK (MIM: 609286)42 and has
been reported in just a single individual with pathogenic
variants inMGME1 (MIM: 615084).43 It is more commonly
associated with autosomal-recessive deficiency of SLC25A4
(cardiomyopathy types of the disease [MIM: 617184 and
615418]), another mtDNA maintenance gene, although
variable mtDNA deletions are usually associated with
dominant pathogenic variants in this gene.
Numerous functions in various cellular organelles have
been reported for C1QBP.16 The clinical manifestation of
our cohort of probands with C1QBP deficiency was mainly
attributed to defects in mitochondrial energy metabolism.
No signs of immunologic dysfunction could be associated
with the complement system.
Given our observations, the main functions of C1QBP
reside within the mitochondrial compartment. How-
ever, the exact mechanism leading to a reduction of
OXPHOS enzymes remains unclear, especially in the
neonatal form.
In summary, we present four individuals with C1QBP
mutations characterized by combined respiratory-chain
deficiency and increased lactate. Disease onset was vari-
able, including intrauterine onset, oligohydramnios, and
neonatal cardiomyopathy leading to early death. Later
onset in childhood or adulthood was associated with exer-
cise intolerance, PEO, and multiple mtDNA deletions.
Cardiomyopathy was found in all forms, which is a rela-
tively unusual presentation in individuals with multiple
mtDNA deletions. Peripheral neuropathy seems to be an
issue; however, the central nervous system seems to be
spared.
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